Information
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 24, 2026 /CNW/ -- USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98
Original sourceAI Summary
Exelixis recently reported substantial 2025 revenues and had its NDA for zanzalintinib accepted by the FDA, signaling strong growth potential in the oncology sector. The expected blockbuster status of upcoming treatments aligns with forecasts predicting significant market expansion, potentially benefiting EXEL shareholders significantly in the coming years.
Sentiment Rationale
With strong revenues and favorable regulatory news, EXEL is positioned for growth. Historical examples in biotech show similar scenarios often lead to positive stock momentum.
Trading Thesis
Buy EXEL ahead of FDA action on zanzalintinib, poised for growth through 2026.
Market-Moving
- Zanzalintinib's potential approval is targeted for December 2026, a crucial catalyst.
- Potential to establish a second oncology franchise may boost EXEL's market position.
- Increasing oncology market size provides a favorable backdrop for EXEL's growth.
Key Facts
- The global oncology market is projected to reach $748.17 billion by 2035.
- Cancer drug revenues may hit $335.2 billion by 2033.
- Exelixis reported $2.1 billion in net product revenues for 2025.
- Zanzalintinib's FDA application for colorectal cancer accepted; action date December 2026.
- Exelixis aims to establish a second oncology franchise with new drug applications.
Companies Mentioned
- Eli Lilly (LLY): Reported strong trial results, increasing competition in oncology.
- Merck (MRK): Received FDA approval for KEYTRUDA in ovarian cancer.
- Gilead Sciences (GILD): Updated label for CAR-T therapy, reflecting competitive advancements.
Corporate Developments
This article fits into 'Corporate Developments' as it highlights significant business milestones for EXEL, including strong revenue growth and critical regulatory paths. This sets the stage for potential stock movement as the company seeks to solidify its position in the expanding oncology market.